Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Specialized Stem Cells Demonstrate Efficacy for Graft versus Host Disease Therapy

By BiotechDaily International staff writers
Posted on 15 Oct 2013
Image: Pluristem PLacental eXpanded (PLX) cell bioreactor (Photo courtesy of Pluristem Therapeutics).
Image: Pluristem PLacental eXpanded (PLX) cell bioreactor (Photo courtesy of Pluristem Therapeutics).
In a preclinical study, specially grown and expanded stem cells demonstrated efficacy for the treatment of Graft versus Host Disease (GvHD) following bone marrow transplantation in mice. A clinical path is now being investigated.

The study was performed using “PLacental eXpanded” (PLX) cells from Pluristem Therapeutics Inc. (Haifa, Israel), a developer of cell-based therapies by expanding noncontroversial placental-derived mesenchymal stem cells via a proprietary 3D micro-environmental process, named PluriX, into therapeutics for a variety of disorders. PLX cells provide a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. They require no tissue matching prior to administration, and thereby addressing part of the global shortfall of matched tissue for bone marrow transplantation (BMT).

In the study conducted at the Department of Bone Marrow Transplantation of the Hebrew University, Hadassah Medical Center (Jerusalem, Israel), mice underwent total body irradiation and after 24 hours received a semi-allogeneic BMT. PLX cells, or the same volumes of the control vehicle, were then injected IV (intravenous) or IM (intramuscular) into the mice concurrently with the BMT (day 0, about 20 hours after irradiation) and 5 days postirradiation. PLX markedly reduced the GvHD score, comprised of weight loss, diarrhea, skin and fur integrity, and survival. This significant (p < 0.05) improvement in the GvHD score occurred in both the IV and IM treatment groups 42 days after transplantation. Moreover, histological examination of the liver revealed reduced hepatic lymphocyte infiltration (a marker for the severity of GvHD) occurring in the PLX-treated groups, also without preference to administration route (IV or IM).

“Based on the results of this preclinical study suggesting our PLX cells may be effective in GvHD, we are pleased with the interest of leading medical institutions to use our PLX cells and will consider a cooperation to advance into a clinical program for this indication,” said Zami Aberman, Chairman and CEO of Pluristem; “[...] this study also gives Pluristem another data point demonstrating PLX cells do not have to be given intravenously to obtain a systemic effect.” This study marks the second time that IM administration of PLX cells has demonstrated a systemic effect with efficacy in a hematological disease and the fourth time when preclinical animal models for other indications are included. Systemic, beneficial effects were also noted in three patients given (under compassionate use) PLX cells IM for bone marrow failure.

Related Links:

Pluristem Therapeutics
Hebrew University – Hadassah Medical Center



Channels

Genomics/Proteomics

view channel
Image: An Austrian Research Center of Industrial Biotechnology researcher is shown working with a laboratory scale continuous antibody purification reactor (Photo courtesy of the Austrian Research Center of Industrial Biotechnology).

Continuous Purification Technique Should Significantly Reduce Antibody Production Costs

An Austrian biotechnology firm has developed a method for the continuous purification of recombinant antibodies from cultures of clarified Chinese hamster ovary (CHO) cells that promises to significantly... Read more

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

“Softer” Mass Spec Techniques Gain Advantage in Biomarker Discovery

Two mass spectrometry (MS) technologies, MALDI and DESI, are increasing in applications as their effectiveness is established, according to Kalorama Information (New York, NY, USA) in its report “Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays,... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.